These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 11346194)

  • 1. The clinical implications of weight gain in schizophrenia.
    Kurzthaler I; Fleischhacker WW
    J Clin Psychiatry; 2001; 62 Suppl 7():32-7. PubMed ID: 11346194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schizophrenia and obesity: impact of antipsychotic medications.
    Wirshing DA
    J Clin Psychiatry; 2004; 65 Suppl 18():13-26. PubMed ID: 15600381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Weight gain during treatment with antipsychotics: clinical relevance, pathophysiology, and therapeutical strategies].
    Himmerich H; Schuld A; Pollmächer T
    Psychiatr Prax; 2004 Nov; 31 Suppl 2():S233-7. PubMed ID: 15586316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of weight gain in patients with schizophrenia.
    Aquila R
    J Clin Psychiatry; 2002; 63 Suppl 4():33-6. PubMed ID: 11913674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schizophrenia, obesity, and antipsychotic medications: what can we do?
    Citrome L; Vreeland B
    Postgrad Med; 2008 Jul; 120(2):18-33. PubMed ID: 18654065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic induced weight gain in schizophrenia:mechanisms and management.
    Rege S
    Aust N Z J Psychiatry; 2008 May; 42(5):369-81. PubMed ID: 18473255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
    Baptista T; Kin NM; Beaulieu S; de Baptista EA
    Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of schizophrenia with obesity, metabolic, and endocrinological disorders.
    Monteleone P; Martiadis V; Maj M
    Psychiatr Clin North Am; 2009 Dec; 32(4):775-94. PubMed ID: 19944883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
    Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
    Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of lifestyle interventions and weight management in schizophrenia.
    Bushe C; Haddad P; Peveler R; Pendlebury J
    J Psychopharmacol; 2005 Nov; 19(6 Suppl):28-35. PubMed ID: 16280335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle.
    Basile VS; Masellis M; McIntyre RS; Meltzer HY; Lieberman JA; Kennedy JL
    J Clin Psychiatry; 2001; 62 Suppl 23():45-66. PubMed ID: 11603885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weight gain with atypical antipsychotics: evidence and insights.
    Henderson DC
    J Clin Psychiatry; 2007; 68 Suppl 12():18-26. PubMed ID: 17956152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic-associated weight gain and clinical outcome parameters.
    Blin O; Micallef J
    J Clin Psychiatry; 2001; 62 Suppl 7():11-21. PubMed ID: 11346191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight change with atypical antipsychotics in the treatment of schizophrenia.
    Haddad P
    J Psychopharmacol; 2005 Nov; 19(6 Suppl):16-27. PubMed ID: 16280334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.
    Casey DE; Haupt DW; Newcomer JW; Henderson DC; Sernyak MJ; Davidson M; Lindenmayer JP; Manoukian SV; Banerji MA; Lebovitz HE; Hennekens CH
    J Clin Psychiatry; 2004; 65 Suppl 7():4-18; quiz 19-20. PubMed ID: 15151456
    [No Abstract]   [Full Text] [Related]  

  • 16. Weight gain associated with use of psychotropic medications.
    Sachs GS; Guille C
    J Clin Psychiatry; 1999; 60 Suppl 21():16-9. PubMed ID: 10548137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
    Turner MS; Stewart DW
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia.
    Weiden PJ
    J Clin Psychiatry; 2007; 68 Suppl 4():34-9. PubMed ID: 17539698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
    Stahl SM; Mignon L; Meyer JM
    Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behavioral therapy for weight loss in patients with schizophrenia.
    Ganguli R
    J Clin Psychiatry; 2007; 68 Suppl 4():19-25. PubMed ID: 17539696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.